Group 1 - The company held its 14th (temporary) meeting of the 11th Board of Directors on January 9, 2026, to discuss several key resolutions [1][4][61] - The board approved the repurchase and cancellation of 119,700 restricted stocks from five former employees who no longer meet the incentive conditions of the 2021 stock incentive plan [1][28][40] - The board also approved the nomination of Liu Wei as an independent director candidate, who will serve as the chair of the audit committee and a member of the remuneration and assessment committee [5][49] Group 2 - The board approved the revision and establishment of several governance systems to enhance operational standards and comply with relevant laws and regulations [8][53] - The company plans to reduce the registered capital of its wholly-owned subsidiary, Hubei Guangji Pharmaceutical Biotechnology Research Institute, by 22 million yuan, bringing the total registered capital down to 28 million yuan [55][59] - The company applied for a comprehensive credit line of 230 million yuan from Zheshang Bank, which includes a general credit limit of 130 million yuan and a low-risk credit limit of 100 million yuan [61][62] Group 3 - The company will hold its first temporary shareholders' meeting of 2026 on January 27, 2026, to discuss the approved resolutions [21][67] - The meeting will include both on-site and online voting options for shareholders [68][75] - The company ensures that all resolutions comply with the relevant laws and regulations, and the independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange [50][71]

Group 1 - The company has approved an internal director compensation plan, which requires shareholder meeting approval [1][8] - The plan applies to full-time directors who have signed labor contracts and are responsible for executing company affairs [1][2] - The annual salary for internal directors is set at 800,000 yuan, with performance-based compensation making up at least 50% of the total [3][4] Group 2 - Performance compensation will be distributed monthly with quarterly settlements, where 25% of the performance pay is settled each quarter based on assessment results [4][5] - The compensation committee is responsible for establishing and modifying assessment standards for internal directors [6] - The compensation is pre-tax, with the company responsible for withholding personal income tax and other applicable fees [7] Group 3 - The company has also approved a capital reduction for its wholly-owned subsidiary, Saint Asia Cultural Tourism Industry Group, reducing registered capital by 32.3749 million yuan [27][30] - Following the reduction, the subsidiary's registered capital will decrease from 100 million yuan to 67.6251 million yuan, with the company retaining 100% ownership [30][32] - This capital reduction does not involve related transactions and will not significantly impact the company's financial status or operations [28][33] Group 4 - The company has approved changes to its registered capital and amendments to its articles of association, increasing registered capital from 128.8 million yuan to 130.445 million yuan due to the issuance of restricted stock [37][38] - The amendments to the articles of association were authorized by the board and do not require shareholder approval [38][39] - The company will handle the necessary business registration changes as per the updated capital structure [38][39]